Furthermore, in NSCLC tumor xenografts, the expression of a tyrosine phosphomimetic Beclin-1 mutant led to reduced autophagy, enhanced tumor growth and resistance to TKI therapy. The gene discussed is BECN1; the disease is neoplasm.